Postmenopausal osteoporosis: Current and future treatment options

P and T

Volumn 32, Issue 7, 2007, Pages 392-402

  McAdam Marx, Carrie ^a   LaFleur, Joanne ^a   Kirkness, Carmen ^a   Asche, Carl ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CATHEPSIN K INHIBITOR; DENOSUMAB; ETIDRONIC ACID; FORTICAL; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PHOSPHATE; PLACEBO; RALOXIFENE; RECLAST; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AGE DISTRIBUTION; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE FRAGILITY; BONE NECROSIS; CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS ULCER; FEVER; FOOD AND DRUG ADMINISTRATION; FRACTURE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERTENSION; JAW DISEASE; KIDNEY FAILURE; LEG CRAMP; METASTASIS; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHINITIS; SEX RATIO; STOMACH ULCER; TREATMENT OUTCOME; TREATMENT RESPONSE; WOMEN'S HEALTH;

EID: 34547741216     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646.
2. World Health Organization. Prevention and Management of Osteoporosis. Geneva: WHO; 2003.
3. Melton LJ 3rd. How many women have osteoporosis now? J Bone Miner Res 1995;10(2):175-177.
4. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12(1):24-35.
5. Shen T, Howe LH, Lumpkin JR. Osteoporosis in Illinois: Analysis of hospital discharge records from 1992 to 1995. Springfield, IL: Illinois Department of Public Health; 1997. Available at www. idph. state.il.us/about/ epi/pdf/epi97-9.pdf. Accessed October 2005.
6. Burge RT, King AB, Balda A, Worley D. Methodology for estimating current and future burden of osteoporosis in state populations. Value Health 2003;6(5):574-583.
7. Kanis J. Diagnosis of osteoporosis and assessment of risk fracture. Lancet 2002;359:1929-1936.
8. Bensen R, Adachi JD, Papaioannou A, et al. Evaluation of easily measured risk factors in the prediction of osteoporotic fractures. BMC Musculoskelet Disord 2005;5:47.
9. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001;12(7):519-528.
10. Broe K, Hannan M, Kiely D, et al. Predicting fractures using bone mineral density: A prospective study of long-term care residents. Osteoporos Int 2000;11:765-771.
11. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332(12):767-773.
12. Dargent-Molina P, Douchin MN, Cormier C, et al. Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS prospective study. Osteoporos Int 2002;13(7):593-599.
13. Dargent-Molina P, Piault S, Breart G. A triage strategy based on clinical risk factors for selecting elderly women for treatment or bone densitometry: The EPIDOS prospective study. Osteoporos Int 2005;16(8):898-906.
14. Fox KM, Cummings SR, Williams E, Stone K Femoral neck and intertrochanteric fractures have different risk factors: A prospective study. Osteoporos Int 2000;11(12):1018-1023.
15. Fujiwara S, Kasagi F, Yamada M, Kodama K. Risk factors for fracture in a Japanese cohort. J Bone Miner Res 1997;12(7):998-1004.
16. Gunnes M, Mellstrom D, Johnell O. How well can a previous fracture indicate a new fracture? A questionnaire study of 29,802 post-menopausal women. Acta Orthop Scand 1998;69(5):508-512.
17. Ismail AA, Cockerill W, Cooper C, et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: Results from the European Prospective Osteoporosis Study. Osteoporos Int 2001;12(2):85-90.
18. Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004;15(3):175-179.
19. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
20. Johnell O, Kanis J, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20(7):1185-1194.
21. Kroger H, Huopio J, Honkanen R, et al. Prediction of fracture risk using axial bone mineral density in a perimenopausal population: Aprospective study. J Bone Miner Res 1995;10(2):302-306.
22. Torgerson DJ, Campbell MK, Thomas RE, Reid DM. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 1996;11(2):293-297.
23. Hotzbuecher C, Ross P, Landsman P, et al. Patients with prior fracture have an increased risk of future fractures: A summary of the literature and statistical significance. J Bone Miner Res 2000; 15(4):721-739.
24. Siris E, Brenneman S, Miller P, et al. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: Results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 2004;19(8): 1215-1220.
25. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19(6): 893-899.
26. De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56(1):208-214.
27. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16(6):581-589.
28. van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(10):3104-3112.
29. Kanis J, Johansoon H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737-742.
30. Kanis J, Johnell O, Oden A, et al. Smoking and fracture risk: A meta-analysis. Osteoporos Int 2005;16:155-162.
31. Silverman SL. Selecting patients for osteoporosis therapy. Curr Osteoporos Rep 2006;4(3):91-95.
32. Brown J, Josse R. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167(10 Suppl):S1-S34.
33. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists: Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis (2001 ed., selected updates for 2003). Endocr Pract 2003;9(6):544-564.
34. Heinemann D. An overview of the National Osteoporosis Foundation clinical practice guidelines. Geriatrics 2000;55(5):31-39.
35. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. November 8, 2005. Available at: www.nof.org/ physguide/attention_phys.htm.
36. Rodan G, Fleisch H. Bisphosphonates: Mechanisms of action. J Clin Invest 1996;97(12):2692-2696.
37. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev 1998;19(1):80-100.
38. Fosamax (alendronate sodium), prescribing information. Whitehouse Station, NJ: Merck; February 2006.
39. Actonel (risedronate sodium), prescribing information. Bridgewater, NJ: Procter & Gamble; August 2006.
40. Boniva (ibandronate), prescribing information. Nutley, NJ: Roche; August 2006.
41. Boniva Injection (ibandronate), prescribing information. Nutley, NJ: Roche; January 2006.
42. Rizzoli R Greenspan SL, Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17(11): 1988-1996.
43. Schnitzer T, Bone HG, Crepaldi G, et al. Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000;12(1):1-12.
44. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of post-menopausal osteoporosis. Calcif Tissue Int 2002;71(2):103-111.
45. Delmas P, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54(6):1838-1846.
46. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006; 65(5):654-661.
47. Didronel (etidronate), prescribing information. North Norwich, NJ: Procter & Gamble; May 2005.
48. Zorneta (zolendronic acid), prescribing information. East Hanover, NJ: Novartis; December 2005.
49. Aredia (pamidronate), prescribing information. East Hanover, NJ: Novartis; February 2006.
50. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis. N Engl J Med 1995;333(22):1437-1444.
51. Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracture. Lancet 1996;348:1535-1541.
52. Cummings S, Black D, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280(24):2077-2082.
53. Black D, Thompson D, Bauer D, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85(11):4118-4124.
54. Bone HG, Hosking D, Devogelaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350(12):1189-1199.
55. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 2006;296(24):2927- 2938.
56. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20(4):433-439.
57. Harris T, Watts N, Genant H, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis: A randomized controlled trial. JAMA 1999;282(4):1344-1352.
58. Harrington J, Ste-Marie L, Brandi M, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with post-menopausal osteoporosis. Calcif Tissue Int 2004;74:129-135.
59. McClung M, Geusens P, Miller P, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344(5): 333-340.
60. Chesnut C, Skag R, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in post-menopausal osteoporosis. J Bone Miner Res 2004;19(8):1241-1249.
61. Watts N, Harris S, Genant H, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323(2):73-79.
62. Harris S, Watts N, Jackson R, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95(6):557-567.
63. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-1822.
64. Evista (raloxifene HCl), prescribing information. Indianapolis, IN: Eli Lilly & Co.; 2003.
65. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-645.
66. Maricic M, Adachi J, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-1143.
67. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study. J Bone Miner Res 2005;20(9):1514-1524.
68. Miacalcin (calcitonin-salmon), prescribing information. East Hanover, NJ: Novartis; June 2006.
69. Fortical (calcitonin-salmon), prescribing information. Minneapolis, MN: Upsher Smith; June 2006.
70. Chesnut C, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study (PROOF). Am J Med 2000;109:267-276.
71. Forteo (teriparatide), prescribing information. Indianapolis, IN: Eli Lilly & Co.; 2004.
72. Dempster D, Cosman F, Kurland E, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 2001;16(10):1846-1853.
73. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;334(19):1434-1441.
74. Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res 2007;22(2):334.
75. Meunier P, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004;350:459-468.
76. Reginster J, Seeman E, De Vernejoul M, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822.
77. Reginster J, Sarlet N, Lejeune E, Leonori L Strontium ranelate: A new treatment for postmenopausal osteoporosis with a dual mode of action. Curr Osteoporos Rep 2005;3(1):30-34.
78. Hodsman A, Hanley D, Ettinger M, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88(11):5212-5220.
79. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 2007;146(5):326-339.
80. NPS receives approvable letter for Preos NDA. Salt Lake City, UT: NPS Pharmaceuticals. Available at: www.npsp.com/news/ releasetxt.php?ReqId=830043. Accessed March 10, 2006.
81. Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: The Fracture Intervention Trial. Osteoporos Int 2001;12:654-660.
82. Schousboe JT, Ensrud KE, Nyman JA, et al. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score >-2.5 for alendronate therapy: A modeling study. J Clin Densitom 2006;9(2):133-143.
83. Schousboe JT, Ensrud KE, Nyman JA et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic postmenopausal women for amino-bisphosphonate therapy. Osteoporos Int 2005;16(12):1883-1893.
84. Schousboe JT, Nyman JA Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142:734-741.
85. Grima D, Burge RT, Becker DL, Tosteson ANA Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 2002;27(9):448-455.
86. Mullins CD, Ohsfeldt R. Modeling the annual costs of post-menopausal prevention therapy: Raloxifene, alendronate or estrogen-progestin therapy. J Manage Care Pharm 2003;9(2):150-158.
87. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355(2):125-137.
88. Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166(11):1209-1217.
89. Cramer JA Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int February 17, 2007 (electronic version).
90. Cosman F, Nieves J, Zion M, et al. Daily and cyclical parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566-575.
91. Black D, Greenspan S, Ensrud K, et al. The effects of parathyroid hormone and alendronate alone or in combination in post-menopausal osteoporosis. N Engl J Med 2003;349(13):1207-1215.
92. Black D, Bilezikian J, Ensrud K, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353(6):555-565.
93. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90(5): 2787-2793.